TRIB NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Trinity Biotech plc · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 12.43 USD
7.2% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -32.4% below the Trend Line and sits at 4.7% of its 52-week range. The latest completed week returned 7.2%, after a 7.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 46/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal.

Setup score 17 out of 100
Latest Close 12.43 USD 7 Aug 2026
1W Return 7.2% latest completed week
4W Return 7.1% short-term follow-through
12W Return -27.9% quarterly tape
Trend Breadth 28.8% 15 of 52 weeks active
Volume Ratio 0.0x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 7.2% Latest completed week; four-week move 7.1%. Indicator stack 16/23 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 37.01% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 46/100 conviction; expected move 38.4%. News sentiment 52/100 63 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -32.4% below the Trend Line and sits at 4.7% of its 52-week range. The latest completed week returned 7.2%, after a 7.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.0x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0612-week average 0.14

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.06Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 7.1% over four weeks, -27.9% over 12 weeks, and -54.8% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W7.2%
4W7.1%
12W-27.9%
26W-48.2%
52W-54.8%
Active trend streak0 weeks
Active weeks in one year15
Trend breadth28.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.16Latest activity-pressure read.
Pressure change-74.0%Four-week change in activity pressure.
Leadership-56.05Latest relative-leadership reading.
RS change8.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 76% Model confidence 71%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength34/100Blend of value, momentum, and quality. Underlying universe rank 67; rank 1 is best.
Value43/100Relative valuation strength. Underlying universe rank 58; rank 1 is best.
Quality40/100Profitability and accounting quality. Underlying universe rank 61; rank 1 is best.
Momentum42/100Medium-term price momentum. Underlying universe rank 59; rank 1 is best.
Growth43/100Revenue and earnings growth. Underlying universe rank 58; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.2x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
0.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
38.6%
Gross profit retained from each unit of revenue.
Operating margin
-55.0%
Operating profit retained from revenue.
Free-cash-flow margin
0.7%
Free cash flow generated from revenue.
Return on invested capital
-29.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.0%
Cash dividends relative to market value.
Buyback yield
-6.5%
Net share repurchases relative to market value.
Shareholder yield
-6.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-6.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

TRIB shows bullish options pressure with a 46/100 conviction score, put-call volume ratio of 0.10, expected move of 38.4%, and Sharemaestro trend signal inactive.

Conviction46/100
Expected move38.4%
Put/call volume0.10
Pressure93
Speculation6
Volatility61
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 63 relevant articles.

13 positive · 43 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move38.4%Nearest-chain priced movement where available.
52-week drawdown-88.0%Distance below the 52-week high.
13-week volatility17.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+37.4%Week of 31 Jul.
Worst week-37.8%Week of 26 Jun.
Latest week+7.2%Week of 7 Aug.

Shape of recent returns

Strong gains8
Modest gains4
Flat weeks0
Modest losses3
Sharp losses11
Recent vol17.1%13-week weekly-return volatility.
Base vol16.7%52-week weekly-return volatility.
Up/down split20/30Count of positive and negative weeks in the 52-week window.
Average skew13.6% / -9.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape15/100

Trend, activity pressure, participation, and risk combine to a 15/100 tape read.

 Indicator analysis15/100

Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.

Activity pressure 0.06; No reversal markers Next-Week ExpectancyNegative 37.01%

Next-week expectancy is negative with a 37.01% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors38/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 84 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options45/100

TRIB shows bullish options pressure with a 46/100 conviction score, put-call volume ratio of 0.10, expected move of 38.4%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 38.4% Sentiment52/100

Weighted news tone is neutral across 63 relevant articles.

Trinity Biotech PLC (TRIB) Institutional Confidence Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202612.43 USD7.2%18.38 USD42.91 USD-1.16-56.0554.5KOff
31 Jul 202611.60 USD37.4%18.70 USD43.56 USD-1.32-57.55268.8KOff
24 Jul 20268.45 USD-16.1%19.06 USD44.41 USD-1.32-69.242.1MOff
17 Jul 202610.06 USD-13.3%19.78 USD45.30 USD-1.05-64.321.1MOff
10 Jul 202611.60 USD2.7%20.34 USD46.20 USD-0.67-61.042.0MOff
3 Jul 202611.29 USD4.3%21.02 USD46.94 USD-0.26-61.8713.0MOff
26 Jun 202610.83 USD-37.8%21.61 USD47.70 USD0.08-63.5459.0MOff
19 Jun 202617.40 USD-10.8%22.29 USD48.55 USD0.35-44.582.1MOff
12 Jun 202619.50 USD-2.6%22.54 USD49.40 USD0.23-36.49633.9KOff
5 Jun 202620.02 USD-5.0%22.77 USD50.27 USD-0.09-33.55728.4KOff
29 May 202621.08 USD16.7%23.05 USD51.15 USD-0.42-33.44787.1KOff
22 May 202618.06 USD4.8%23.35 USD51.96 USD-0.85-41.57686.8KOff
15 May 202617.23 USD-5.4%23.74 USD52.73 USD-0.82-43.96492.6KOff
8 May 202618.21 USD-0.1%24.16 USD53.54 USD-0.53-41.62287.8KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context